Company intelligence / Profile preview

Talon Group

South San Francisco, California, United Statestalon.us ↗

Ownership: Private
Development stage: Other

Overview

Talon Therapeutics was a US-based oncology-focused biopharmaceutical company best known for developing Marqibo® (vincristine sulfate liposome injection), which received FDA accelerated approval for relapsed adult Ph(-) acute lymphoblastic leukemia after two or more prior therapies. The company's pipeline also included Menadione Topical Lotion for skin toxicities related to anti-EGFR cancer therapies. In July/August 2013 it was acquired by Spectrum Pharmaceuticals and ceased independent operations.

Therapeutic areas: OncologyDermatology
Modalities: Liposomal formulationSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Talon Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Talon Group.

Explore the full profile